Andera and LSP lead $84m series-B for Artios
Andera Partners and Life Sciences Partners (LSP) have led an $84m series-B funding round for UK-based biotech company Artios Pharma.
New investors Pfizer Ventures and Novartis Venture Fund (NVF) also took part in the round alongside existing backers Arix Bioscience, SV Health Investors, M Ventures, IP Group and Abbvie Ventures.
The company will look to undertake clinical proof-of-concept trials for its programme targeting DNA polymerase theta.
Andera partner Raphael Wisniewski, LSP managing partner Rene Kuijten and Pfizer Ventures vice-president Barbara Dalton will take on director roles on the Artios board, while NVF principal Florian Muellershausen will join as an observer.
Previous funding
Imperial Innovations and SV Life Sciences took part in a £25m series-A for Artios in September 2016, alongside Abbvie, Merck Ventures, Arix and Sixth Element Capital. Imperial invested £5.1m for a 14.9% stake in the company.
Company
Founded in 2016 as a spinout from Cancer Research UK, Cambridge-headquartered Artios is a biotechnology company focusing on the development of DNA damage-response programmes for the treatment of cancers.
People
Andera Partners – Raphael Wisniewski (partner).
Life Sciences Partners – Rene Kuijten (managing partner).
Artios Pharma – Niall Martin (CEO).
More on Early-stage
Sidekick spinoffs: Insurtech scale-ups attract PE interest
Investment set to break EUR 1.1bn mark this year as sponsors seek for rising stars
World Fund leads EUR 128m raise for quantum computing group IQM
Series-A2 for Finnish startup focused on combating the climate crisis also backed by the EIB
Gorillas raises circa USD 1bn in Delivery Hero-led Series C
New funding comes just seven months after a Series B, with the company doubling in value
French mega-rounds shoot up in 2021
France has already seen as many rounds of EUR 100m and above than in 2019 and 2020 combined, Unquote Data shows
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater